Comparative Pharmacology
Head-to-head clinical analysis: RUXOLITINIB versus XELJANZ XR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: RUXOLITINIB versus XELJANZ XR.
Ruxolitinib vs XELJANZ XR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective inhibitor of Janus-associated kinases (JAK) JAK1 and JAK2, reducing cytokine signaling and hematopoiesis.
Janus kinase (JAK) inhibitor; inhibits JAK1, JAK2, JAK3, and TYK2, modulating cytokine signaling pathways involved in immune responses.
Myelofibrosis: 5-25 mg orally twice daily based on platelet count; Polycythemia Vera: 10 mg orally twice daily; Graft-versus-Host Disease: 5-10 mg orally twice daily.
11 mg orally once daily, with or without food, for rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis; for ulcerative colitis, use 5 mg twice daily if switching from immediate-release tofacitinib 5 mg twice daily.
None Documented
None Documented
Clinical Note
moderateRuxolitinib + Digoxin
"Ruxolitinib may increase the bradycardic activities of Digoxin."
Clinical Note
moderateRuxolitinib + Digitoxin
"Ruxolitinib may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateRuxolitinib + Deslanoside
"Ruxolitinib may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateRuxolitinib + Acetyldigitoxin
"Ruxolitinib may decrease the cardiotoxic activities of Acetyldigitoxin."
The terminal elimination half-life of ruxolitinib is approximately 3 hours for the parent drug. However, the pharmacodynamic half-life for JAK2 inhibition is longer (up to 8-12 hours) due to sustained target suppression.
Terminal elimination half-life is approximately 3.3 hours for the immediate-release formulation; for XELJANZ XR (extended-release), effective half-life is prolonged due to extended absorption, but terminal half-life remains ~3.3 hours. Clinical context: Twice-daily dosing for IR, once-daily for XR.
Ruxolitinib is primarily metabolized in the liver, and its metabolites are excreted renally. Approximately 74% of the dose is eliminated in urine (mainly as metabolites) and 22% in feces (as unchanged drug and metabolites).
Renal excretion accounts for approximately 70% of total clearance (30% unchanged drug, 40% as metabolites); biliary/fecal excretion accounts for approximately 30% of total clearance (metabolites).
Category D/X
Category C
JAK Inhibitor
JAK Inhibitor